^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IDP-121

i
Other names: IDP-121, IDP 121
Associations
Trials
Company:
IDP Discovery Pharma
Drug class:
MYC inhibitor
Associations
Trials
over1year
CASSANDRA: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=37, Recruiting, IDP Discovery Pharma S.L. | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
IDP-121
over1year
New P1/2 trial
|
IDP-121
over3years
[VIRTUAL] A first-in-class c-MYC inhibitor shows in vivo efficacy in lung cancer models and has appropriate drug-like characteristics (AACR 2021)
The efficacy in hematological tumors of IDP-121 have been also demonstrated in vivo (see Abstract 2). In addition, IDP-121 has progressed through GLP toxicology studies without evidence of major systemic toxicity, allowing for the first viable Myc-targeted therapy to enter Phase 1 clinical trials in 2021.
Preclinical
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC expression
|
IDP-121